Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Upcoming efficacy % @360-days

<< Previous

Bullboard Posts

Next >>

Comment by ScienceFirston Aug 10, 2022 4:42pm

267 Views

Post# 34886294

RE:RE:RE:RE:RE:Upcoming efficacy % @360-days

If BCG has been able to be given 10-24x to patients, there's no reason for us to give it 3-4x for cases that might not deliver CR @450-days.

We have a possibility to displace BCG totally. We just need more data to confirm it. And our TLD1433 is also good for MIBC, which is not the case for BCG. Chemo is required. So between TLD1433 and chemo for MIBC, the choice will be easy. A big pharma will want this market share (MIBC = 30% of the bladder market).

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals